Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy
about
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemiaGenetics of CD33 in Alzheimer's disease and acute myeloid leukemia.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyMicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinCellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.Associations of genetic polymorphisms of Siglecs with human diseases.Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.Gemtuzumab ozogamicin in acute myeloid leukemia.Antibody-Based Treatment of Acute Myeloid Leukemia.CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.
P2860
Q34742630-7634150F-3992-40E5-8EE6-5B873B39B12EQ35837399-07017A28-DFCA-4E89-9F6F-BF115696D770Q36058588-5B0AA043-6AA8-427D-B322-D8BF68B0E645Q36511384-F0718D62-F1E5-4CEA-9A29-69422A387E5BQ36932014-DFC2A465-702E-4CA9-8D1B-37F2AEADB245Q37512086-BDFEBA2D-BF5C-4161-A895-8FF30B30B829Q37645063-AC3CD9F8-2BB1-4D3A-878C-2A63A03EBADFQ38212860-DA4B4631-5EA2-4B35-9DC3-2BA0E78FFE7BQ38232465-866E1CF9-B444-45FA-99D1-F93DEFA6AE5AQ38598881-40226C00-EF92-4F14-9CC1-C0C8C2984206Q38728718-F6DF4FC8-14FE-4765-90CD-CD454B81DE49Q38979277-A0D4BDF9-D091-477C-A8D8-32B867A62C49Q46426075-45EFDD1E-73DB-4C5B-A698-DFCAD59B8B71Q50102761-CADE7557-068A-4FCD-9F17-B00CE663EF2B
P2860
Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Clinical significance of CD33 ...... amicin-containing chemotherapy
@ast
Clinical significance of CD33 ...... amicin-containing chemotherapy
@en
type
label
Clinical significance of CD33 ...... amicin-containing chemotherapy
@ast
Clinical significance of CD33 ...... amicin-containing chemotherapy
@en
prefLabel
Clinical significance of CD33 ...... amicin-containing chemotherapy
@ast
Clinical significance of CD33 ...... amicin-containing chemotherapy
@en
P2093
P2860
P1476
Clinical significance of CD33 ...... amicin-containing chemotherapy
@en
P2093
Alan Gamis
Amit K Mitra
Betsy Hirsch
Janet Franklin
Jatinder K Lamba
Jeffrey E Rubnitz
Jessica A Pollard
Leslie Mortland
Michael R Loken
Raul C Ribeiro
P2860
P304
P356
10.1158/1078-0432.CCR-12-3115
P407
P577
2013-02-26T00:00:00Z